Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343(13):938–952.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Orton S-M, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932–936.
   PubMed Web of Science ®Google Scholar
• Cree BA, Gourraud P-A, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499–510.
   PubMed Web of Science ®Google Scholar
• Bermel RA, Rae-Grant AD, Fox RJ. Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy. Mult Scler J. 2010;16(11):1335–1340.
   PubMedGoogle Scholar
• Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169–180.
   PubMed Web of Science ®Google Scholar
• Nave K-A. Myelination and support of axonal integrity by glia. Nature. 2010;468(7321):244–252.
   PubMed Web of Science ®Google Scholar
• Franklin RJM, Ffrench-constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008;9(11):839–855.
   PubMed Web of Science ®Google Scholar
• Duncan ID, Radcliff AB, Heidari M, et al. The adult oligodendrocyte can participate in remyelination. Proc Nat Acad Sci. 2018;115(50):E11807.
   PubMed Web of Science ®Google Scholar
• Yeung MSY, Djelloul M, Steiner E, et al. Dynamics of oligodendrocyte generation in multiple sclerosis. Nature. 2019;566(7745):538–542.
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–717.
   PubMed Web of Science ®Google Scholar
• Popescu BFG, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum. 2013;19(4):901–921.
   PubMedGoogle Scholar
• Metz I, Weigand SD, Popescu BFG, et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol. 2014;75(5):728–738.
   PubMed Web of Science ®Google Scholar
• Rodriguez M. Virus-induced demyelination in mice: “Dying Back” of oligodendrocytes. Mayo Clin Proc. 1985;60(7):433–438.
   PubMed Web of Science ®Google Scholar
• Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008;63(1):16–25.
   PubMed Web of Science ®Google Scholar
• Prineas JW, Parratt JD. Oligodendrocytes and the early multiple sclerosis lesion. Ann Neurol. 2012;72(1):18–31.
   PubMed Web of Science ®Google Scholar
• Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710–721.
   PubMed Web of Science ®Google Scholar
• Kuhlmann T, Ludwin S, Prat A, et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2017;133(1):13–24.
   PubMed Web of Science ®Google Scholar
• Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci. 1998;18(2):601.
   PubMed Web of Science ®Google Scholar
• Chang A, Nishiyama A, Peterson J, et al. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000;20(17):6404.
   PubMed Web of Science ®Google Scholar
• Wilson HC, Scolding NJ, Raine CS. Co-expression of PDGF α receptor and NG2 by oligodendrocyte precursors in human CNS and multiple sclerosis lesions. J Neuroimmunol. 2006;176(1):162–173.
   PubMed Web of Science ®Google Scholar
• Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006;129(12):3165–3172.
   PubMedGoogle Scholar
• Nicaise AM, Wagstaff LJ, Willis CM, et al. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc Nat Acad Sci. 2019;116(18):9030.
   PubMed Web of Science ®Google Scholar
• Jäkel S, Agirre E, Mendanha Falcão A, et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 2019;566(7745):543–547.
   PubMed Web of Science ®Google Scholar
• Procaccini C, De Rosa V, Pucino V, et al. Animal models of Multiple Sclerosis. Eur J Pharmacol. 2015;759:182–191.
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bradl M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 2017;133(2):223–244.
   PubMed Web of Science ®Google Scholar
• Bjelobaba I, Begovic-Kupresanin V, Pekovic S, et al. Animal models of multiple sclerosis: focus on experimental autoimmune encephalomyelitis. J Neurosci Res. 2018;96(6):1021–1042.
   PubMed Web of Science ®Google Scholar
• Burrows DJ, McGown A, Jain SA, et al. Animal models of multiple sclerosis: from rodents to zebrafish. Mult Scler J. 2018;25(3):306–324.
   PubMed Web of Science ®Google Scholar
• Vesterinen HM, Sena ES, Ffrench-constant C, et al. Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler J. 2010;16(9):1044–1055.
   PubMed Web of Science ®Google Scholar
• Piddlesden SJ, Lassmann H, Zimprich F, et al. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol. 1993;143(2):555–564.
   PubMed Web of Science ®Google Scholar
• Mei F, Lehmann-Horn K, Shen Y-A-A, et al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. eLife. 2016;5:e18246.
   PubMed Web of Science ®Google Scholar
• Huseby ES, Liggitt D, Brabb T, et al. A pathogenic role for myelin-specific Cd8+ T cells in a model for multiple sclerosis. J Exp Med. 2001;194(5):669–676.
   PubMed Web of Science ®Google Scholar
• Saxena A, Bauer J, Scheikl T, et al. Cutting edge: multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J Immunol. 2008;181(3):1617.
   PubMed Web of Science ®Google Scholar
• Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci. 2003;206(2):187–191.
   PubMed Web of Science ®Google Scholar
• Sun D, Whitaker JN, Huang Z, et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol. 2001;166(12):7579.
   PubMed Web of Science ®Google Scholar
• DePaula-Silva AB, Hanak TJ, Libbey JE, et al. Theiler’s murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: models for multiple sclerosis and epilepsy. J Neuroimmunol. 2017;308:30–42.
   PubMed Web of Science ®Google Scholar
• Katz-Levy Y, Neville KL, Girvin AM, et al. Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler’s virus–infected mice. J Clin Invest. 1999;104(5):599–610.
   PubMed Web of Science ®Google Scholar
• Gerhauser I, Li L, Li D, et al. Dynamic changes and molecular analysis of cell death in the spinal cord of SJL mice infected with the BeAn strain of Theiler’s murine encephalomyelitis virus. Apoptosis. 2018;23(2):170–186.
   PubMed Web of Science ®Google Scholar
• Raddatz BB, Sun W, Brogden G, et al. Central nervous system demyelination and remyelination is independent from systemic cholesterol level in Theiler’s murine encephalomyelitis. Brain Pathol. 2016;26(1):102–119.
   PubMed Web of Science ®Google Scholar
• Gerhauser I, Hansmann F, Ciurkiewicz M, et al. Facets of Theiler’s murine encephalomyelitis virus-induced diseases: an update. Int J Mol Sci. 2019;20(2):448.
   Web of Science ®Google Scholar
• Blakemore WF. The case for a central nervous system (CNS) origin for the Schwann cells that remyelinate CNS axons following concurrent loss of oligodendrocytes and astrocytes. Neuropathol Appl Neurobiol. 2005;31(1):1–10.
   PubMed Web of Science ®Google Scholar
• Hesse A, Wagner M, Held J, et al. In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. Neurobiol Dis. 2010;37(2):362–369.
   PubMed Web of Science ®Google Scholar
• Mason JL, Toews A, Hostettler JD, et al. Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions. Am J Pathol. 2004;164(5):1673–1682.
   PubMed Web of Science ®Google Scholar
• Gudi V, Gingele S, Skripuletz T, et al. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front Cell Neurosci. 2014;8:73.
   PubMed Web of Science ®Google Scholar
• Kipp M, Nyamoya S, Hochstrasser T, et al. Multiple sclerosis animal models: a clinical and histopathological perspective. Brain Pathol. 2017;27(2):123–137.
   PubMed Web of Science ®Google Scholar
• Jäkel S, Dimou L. Glial cells and their function in the adult brain: a journey through the history of their ablation. Front Cell Neurosci. 2017;11:24.
   PubMed Web of Science ®Google Scholar
• Chow BM, Li YQ, Wong CS. Radiation-induced apoptosis in the adult central nervous system is p53-dependent. Cell Death Differ. 2000;7(8):712–720.
   PubMed Web of Science ®Google Scholar
• Kurita H, Kawahara N, Asai A, et al. Radiation-induced apoptosis of oligodendrocytes in the adult rat brain. Neurol Res. 2001;23(8):869–874.
   PubMed Web of Science ®Google Scholar
• Begolly S, Olschowka JA, Love T, et al. Fractionation enhances acute oligodendrocyte progenitor cell radiation sensitivity and leads to long term depletion. Glia. 2018;66(4):846–861.
   PubMed Web of Science ®Google Scholar
• Irvine K-A, Blakemore WF. A different regional response by mouse oligodendrocyte progenitor cells (OPCs) to high-dose X-irradiation has consequences for repopulating OPC-depleted normal tissue. Eur J Neurosci. 2007;25(2):417–424.
   PubMed Web of Science ®Google Scholar
• Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain. 2008;131(6):1464–1477.
   PubMedGoogle Scholar
• Chari DM, Blakemore WF. Efficient recolonisation of progenitor-depleted areas of the CNS by adult oligodendrocyte progenitor cells. Glia. 2002;37(4):307–313.
   PubMed Web of Science ®Google Scholar
• Atkinson SL, Li Y-Q, Wong CS. Apoptosis and proliferation of oligodendrocyte progenitor cells in the irradiated rodent spinal cord. Int J Radiat Oncol Biol Phys. 2005;62(2):535–544.
   PubMed Web of Science ®Google Scholar
• Lumniczky K, Szatmári T, Sáfrány G. Ionizing radiation-induced immune and inflammatory reactions in the brain. Front Immunol. 2017;8:517.
   PubMed Web of Science ®Google Scholar
• Birey F, Aguirre A. Age-dependent netrin-1 signaling regulates NG2+ glial cell spatial homeostasis in normal adult gray matter. J Neurosci. 2015;35(17):6946.
   PubMed Web of Science ®Google Scholar
• Birey F, Kloc M, Chavali M, et al. Genetic and stress-induced loss of NG2 glia triggers emergence of depressive-like behaviors through reduced secretion of FGF2. Neuron. 2015;88(5):941–956.
   PubMed Web of Science ®Google Scholar
• Wright J, Zhang G, Yu T-S, et al. Age-related changes in the oligodendrocyte progenitor pool influence brain remodeling after injury. Dev Neurosci. 2010;32(5–6):499–509.
   PubMed Web of Science ®Google Scholar
• Hesp ZC, Yoseph RY, Suzuki R, et al. Proliferating NG2-cell-dependent angiogenesis and scar formation alter axon growth and functional recovery after spinal cord injury in mice. J Neurosci. 2018;38(6):1366.
   PubMed Web of Science ®Google Scholar
• Nakano M, Tamura Y, Yamato M, et al. NG2 glial cells regulate neuroimmunological responses to maintain neuronal function and survival. Sci Rep. 2017;7(1):42041.
   PubMedGoogle Scholar
• Li R, Bernau K, Sandbo N, et al. Pdgfra marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury response. Elife. 2018;7. DOI:10.7554/eLife.36865.
   Web of Science ®Google Scholar
• Robins SC, Villemain A, Liu X, et al. Extensive regenerative plasticity among adult NG2-glia populations is exclusively based on self-renewal. Glia. 2013;61(10):1735–1747.
   PubMed Web of Science ®Google Scholar
• Doetsch F, Caillé I, Lim DA, et al. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 1999;97(6):703–716.
   PubMed Web of Science ®Google Scholar
• Singer BH, Jutkiewicz EM, Fuller CL, et al. Conditional ablation and recovery of forebrain neurogenesis in the mouse. J Comp Neurol. 2009;514(6):567–582.
   PubMed Web of Science ®Google Scholar
• Garthe A, Behr J, Kempermann G. Adult-generated hippocampal neurons allow the flexible use of spatially precise learning strategies. PLoS One. 2009;4(5):e5464.
   PubMed Web of Science ®Google Scholar
• Kerezoudis P, Goyal A, Lu VM, et al. The role of radiation and chemotherapy in adult patients with high-grade brainstem gliomas: results from the national cancer database. J Neurooncol. 2020;146(2):303–310.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Gibson EM, Nagaraja S, Ocampo A, et al. Methotrexate chemotherapy induces persistent Tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell. 2019;176(1–2):43–55.e13.
   PubMed Web of Science ®Google Scholar
• Wang S, Lai X, Deng Y, et al. Correlation between mouse age and human age in anti-tumor research: significance and method establishment. Life Sci. 2020;242:117242.
   PubMed Web of Science ®Google Scholar
• Cantuti-Castelvetri L, Fitzner D, Bosch-Queralt M, et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science. 2018;359(6376):684–688.
   PubMed Web of Science ®Google Scholar
• Neumann B, Baror R, Zhao C, et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell. 2019;25(4):473–485.e8.
   PubMed Web of Science ®Google Scholar
• Rivera AD, Pieropan F, Chacon‐De‐La‐Rocha I, et al. Functional genomic analyses highlight a shift in Gpr17-regulated cellular processes in oligodendrocyte progenitor cells and underlying myelin dysregulation in the aged mouse cerebrum. Aging Cell. 2021;20(4):e13335.
   PubMed Web of Science ®Google Scholar
• Papadopoulos D, Magliozzi R, Mitsikostas DD, et al. Aging, cellular senescence, and progressive multiple sclerosis. Front Cell Neurosci. 2020;14:178.
   PubMed Web of Science ®Google Scholar
• Koutsoudaki PN, Papadopoulos D, Passias P-G, et al. Cellular senescence and failure of myelin repair in multiple sclerosis. Mech Ageing Dev. 2020;192:111366.
   PubMed Web of Science ®Google Scholar
• Zhang P, Kishimoto Y, Grammatikakis I, et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat Neurosci. 2019;22(5):719–728.
   PubMed Web of Science ®Google Scholar
• Burns TC, Verfaillie CM. From mice to mind: strategies and progress in translating neuroregeneration. Eur J Pharmacol. 2015;759:90–100.
   PubMed Web of Science ®Google Scholar
• Burns TC, Li MD, Mehta S, et al. Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: a systematic bioinformatics-based critique of preclinical models. Eur J Pharmacol. 2015;759:101-117.
   Web of Science ®Google Scholar
• Van Der Star BJ, Y.S. Vogel D, Kipp M, et al. In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets. 2012;11(5):570–588.
   PubMed Web of Science ®Google Scholar
• Eshaghi A, Young AL, Wijeratne PA, et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat Commun. 2021;12(1):2078.
   PubMed Web of Science ®Google Scholar
• Tallantyre EC, Bø L, Al-Rawashdeh O, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler. 2010;16(4):406–411.
   PubMed Web of Science ®Google Scholar
• Barkhof F, Calabresi PA, Miller DH, et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5(5):256–266.
   PubMed Web of Science ®Google Scholar
• Steenwijk MD, Geurts JJG, Daams M, et al. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain. 2016;139(Pt 1):115–126.
   PubMed Web of Science ®Google Scholar
• Fuchs TA, Carolus K, Benedict RHB, et al. Impact of focal white matter damage on localized subcortical gray matter atrophy in multiple sclerosis: a 5-year study. AJNR Am J Neuroradiol. 2018;39(8):1480–1486.
   PubMed Web of Science ®Google Scholar
• Petzold A, De Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010;9(9):921–932.
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705–2712.
   PubMed Web of Science ®Google Scholar
• Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10(4):225–238.
   PubMed Web of Science ®Google Scholar
• Correale J, Marrodan M, Ysrraelit MC. Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis. Biomedicines. 2019;7(1):14.
   PubMed Web of Science ®Google Scholar
• Sherman LS, Back SA. A ‘GAG’ reflex prevents repair of the damaged CNS. Trends Neurosci. 2008;31(1):44–52.
   PubMed Web of Science ®Google Scholar
• Lau LW, Cua R, Keough MB, et al. Pathophysiology of the brain extracellular matrix: a new target for remyelination. Nat Rev Neurosci. 2013;14(10):722–729.
   PubMed Web of Science ®Google Scholar
• Harlow DE, Macklin WB. Inhibitors of myelination: ECM changes, CSPGs and PTPs. Exp Neurol. 2014;251:39–46.
   PubMed Web of Science ®Google Scholar
• van Horssen J, Schreibelt G, Drexhage J, et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med. 2008;45(12):1729–1737.
   PubMed Web of Science ®Google Scholar
• Stoffels JM, de Jonge JC, Stancic M, et al. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination. Brain. 2013;136(Pt 1):116–131.
   PubMedGoogle Scholar
• Tremblay M, Stevens B, Sierra A, et al. The role of microglia in the healthy brain. J Neurosci. 2011;31(45):16064–16069.
   PubMed Web of Science ®Google Scholar
• Ueno M, Fujita Y, Tanaka T, et al. Layer V cortical neurons require microglial support for survival during postnatal development. Nat Neurosci. 2013;16(5):543–551.
   PubMed Web of Science ®Google Scholar
• Liu YU, Ying Y, Li Y, et al. Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling. Nat Neurosci. 2019;22(11):1771–1781.
   PubMed Web of Science ®Google Scholar
• Umpierre AD, Bystrom LL, Ying Y, et al. Microglial calcium signaling is attuned to neuronal activity in awake mice. Elife. 2020;9. DOI:10.7554/eLife.56502.
   PubMed Web of Science ®Google Scholar
• Hughes AN, Appel B. Microglia phagocytose myelin sheaths to modify developmental myelination. Nat Neurosci. 2020;23(9):1055–1066.
   PubMed Web of Science ®Google Scholar
• Hagemeyer N, Hanft K-M, Akriditou M-A, et al. Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood. Acta Neuropathol. 2017;134(3):441–458.
   PubMed Web of Science ®Google Scholar
• Voet S, Prinz M, Van Loo G. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med. 2019;25(2):112–123.
   PubMed Web of Science ®Google Scholar
• Lloyd AF, Miron VE. The pro-remyelination properties of microglia in the central nervous system. Nat Rev Neurol. 2019;15(8):447–458.
   PubMed Web of Science ®Google Scholar
• Guerrero BL, Sicotte NL. Microglia in multiple sclerosis: friend or Foe? Front Immunol. 2020;11:374.
   PubMedGoogle Scholar
• Zia S, Rawji KS, Michaels NJ, et al. Microglia diversity in health and multiple sclerosis. Front Immunol. 2020;11:588021.
   PubMedGoogle Scholar
• Li MD, Burns TC, Kumar S, et al. Aging-like changes in the transcriptome of irradiated microglia. Glia. 2015;63(5):754–767.
   Web of Science ®Google Scholar
• Rawji KS, Gonzalez Martinez GA, Sharma A, et al. The role of astrocytes in remyelination. Trends Neurosci. 2020;43(8):596–607.
   PubMed Web of Science ®Google Scholar
• Domingues HS, Portugal CC, Socodato R, et al. Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair. Front Cell Dev Biol. 2016;4:71-87.
   Web of Science ®Google Scholar
• Dong Y, Yong VW. When encephalitogenic T cells collaborate with microglia in multiple sclerosis. Nat Rev Neurol. 2019;15(12):704–717.
   PubMed Web of Science ®Google Scholar
• Pennati A, Nylen EA, Duncan ID, et al. Regulatory B cells normalize CNS myeloid cell content in a mouse model of multiple sclerosis and promote oligodendrogenesis and remyelination. J Neurosci. 2020;40(26):5105–5115.
   PubMed Web of Science ®Google Scholar
• Goldman SA, Nedergaard M, Windrem MS. Modeling cognition and disease using human glial chimeric mice. Glia. 2015;63(8):1483–1493.
   PubMed Web of Science ®Google Scholar
• Windrem MS, Schanz SJ, Morrow C, et al. A competitive advantage by neonatally engrafted human glial progenitors yields mice whose brains are chimeric for human glia. J Neurosci. 2014;34(48):16153–16161.
   PubMed Web of Science ®Google Scholar
• Mei F, Fancy SPJ, Shen Y-A-A, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014;20(8):954–960.
   PubMed Web of Science ®Google Scholar
• Li Z, He Y, Fan S, et al. Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination. Neurosci Bull. 2015;31(5):617–625.
   PubMed Web of Science ®Google Scholar
• Welliver RR, Polanco JJ, Seidman RA, et al. Muscarinic receptor M3R signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells. J Neurosci. 2018;38(31):6921.
   PubMed Web of Science ®Google Scholar
• Larocca JN, Almazan G. Acetylcholine agonists stimulate mitogen-activated protein kinase in oligodendrocyte progenitors by muscarinic receptors. J Neurosci Res. 1997;50(5):743–754.
   PubMed Web of Science ®Google Scholar
• De Angelis F, Bernardo A, Magnaghi V, et al. Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation, and differentiation. Dev Neurobiol. 2012;72(5):713–728.
   PubMed Web of Science ®Google Scholar
• Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481–2489.
   PubMed Web of Science ®Google Scholar
• Assessment of clemastine fumarate as a remyelinating agent in acute optic neuritis (ReCOVER). [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT02521311
   Google Scholar
• Fujimoto K, Mizuguchi H, Fukui H, et al. Presynaptic localization of histamine H3-receptors in rat brain. Biochem Biophys Res Commun. 1991;177(3):907–912.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhen W, Guo T, et al. Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination. PLOS ONE. 2017;12(12):e0189380.
   PubMed Web of Science ®Google Scholar
• Rangon C-M, Schang A-L, Van Steenwinckel J, et al. Myelination induction by a histamine H3 receptor antagonist in a mouse model of preterm white matter injury. Brain Behav Immun. 2018;74:265–276.
   PubMed Web of Science ®Google Scholar
• Schwartzbach CJ, Grove RA, Brown R, et al. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. J Neurol. 2017;264(2):304–315.
   PubMed Web of Science ®Google Scholar
• Bordet T, Berna P, Abitbol J-L, et al. Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals. 2010;3(2):345–368.
   Google Scholar
• Magalon K, Zimmer C, Cayre M, et al. Olesoxime accelerates myelination and promotes repair in models of demyelination. Ann Neurol. 2012;71(2):213–226.
   PubMed Web of Science ®Google Scholar
• Magalon K, Le Grand M, El Waly B, et al. Olesoxime favors oligodendrocyte differentiation through a functional interplay between mitochondria and microtubules. Neuropharmacology. 2016;111:293–303.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Y, Han W, et al. TRO19622 promotes myelin repair in a rat model of demyelination. Int J Neurosci. 2013;123(11):810–822.
   PubMed Web of Science ®Google Scholar
• Pelletier J, Ranjeva J-P,  Tourbah A, et al. Results of a Phase 1b study to confirm safety and tolerability of olesoxime in multiple sclerosis patients (P7.282). Neurology. 2015;84(14 Supplement): P7.282.
   Google Scholar
• Safety study of olesoxime in patients with stable relapsing remitting multiple sclerosis treated with interferon beta. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT01808885
   Google Scholar
• Huang JK, Jarjour AA, Nait Oumesmar B, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci. 2011;14(1):45–53.
   PubMed Web of Science ®Google Scholar
• Chiang ACA, Seua AV, Singhmar P, et al. Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice. Acta Neuropathol Commun. 2020;8(1):193.
   PubMed Web of Science ®Google Scholar
• A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist’s ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial. [cited 2021 Apr 28]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003145-99/GB
   Google Scholar
• Shen X, Liu W, Gao X, et al. Mechanisms of oxidase and superoxide dismutation-like activities of Gold, Silver, Platinum, and Palladium, and their alloys: a general way to the activation of molecular oxygen. J Am Chem Soc. 2015;137(50):15882–15891.
   PubMed Web of Science ®Google Scholar
• Fünfschilling U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485(7399):517–521.
   PubMed Web of Science ®Google Scholar
• Robinson AP, Zhang JZ, Titus HE, et al. Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci Rep. 2020;10(1):1936.
   PubMed Web of Science ®Google Scholar
• Aghaie T, Jazayeri MH, Avan A, et al. Gold nanoparticles and polyethylene glycol alleviate clinical symptoms and alter cytokine secretion in a mouse model of experimental autoimmune encephalomyelitis. IUBMB Life. 2019;71(9):1313–1321.
   PubMed Web of Science ®Google Scholar
• Nanocrystalline Gold to treat remyelination failure in chronic optic neuropathy in multiple sclerosis. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT03536559
   Google Scholar
• A multi-center, open-label long-term extension study of CNM-Au8 in patients with stable relapsing multiple sclerosis. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT04626921
   Google Scholar
• Zhornitsky S, Yong VW, Weiss S, et al. Prolactin in multiple sclerosis. Mult Scler J. 2012;19(1):15–23.
   PubMed Web of Science ®Google Scholar
• De Giglio L, Marinelli F, Prosperini L, et al. Relationship between prolactin plasma levels and white matter volume in women with multiple sclerosis. Mediators Inflamm. 2015;2015:732539.
   PubMed Web of Science ®Google Scholar
• Gregg C, Shikar V, Larsen P, et al. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci. 2007;27(8):1812.
   PubMed Web of Science ®Google Scholar
• Correale J, Farez MF, Ysrraelit MC. Role of prolactin in B cell regulation in multiple sclerosis. J Neuroimmunol. 2014;269(1):76–86.
   PubMed Web of Science ®Google Scholar
• Costanza M, Pedotti R. Prolactin: friend or Foe in central nervous system autoimmune inflammation? Int J Mol Sci. 2016;17(12):2026.
   PubMed Web of Science ®Google Scholar
• Koch MW, Liu W-Q, Camara-Lemarroy C, et al. Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis. J Neuroimmunol. 2019;334:576974.
   PubMed Web of Science ®Google Scholar
• Chandran P, Upadhyay J, Markosyan S, et al. Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience. 2012;202:446–453.
   PubMed Web of Science ®Google Scholar
• Wang H-N, Liu G-H, Zhang R-G, et al. Quetiapine ameliorates schizophrenia-like behaviors and protects myelin integrity in cuprizone intoxicated mice: the involvement of notch signaling pathway. Int J Neuropsychopharmacol. 2016;19(2): pyv088.
   Web of Science ®Google Scholar
• Xu H, Yang H, McConomy B, et al. Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics. Front Behav Neurosci. 2010;4:8.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang H, Wang L, et al. Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr Res. 2012;138(1):8–17.
   PubMed Web of Science ®Google Scholar
• Mei F, Guo S, He Y, et al. Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation. PLOS ONE. 2012;7(8):e42746.
   PubMed Web of Science ®Google Scholar
• Bi X, Zhang Y, Yan B, et al. Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice. J Neurochem. 2012;123(1):14–20.
   PubMed Web of Science ®Google Scholar
• Xiao L, Xu H, Zhang Y, et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry. 2008;13(7):697–708.
   PubMed Web of Science ®Google Scholar
• Xu H, Yang H-J, Li X-M. Differential effects of antipsychotics on the development of rat oligodendrocyte precursor cells exposed to cuprizone. Eur Arch Psychiatry Clin Neurosci. 2014;264(2):121–129.
   PubMed Web of Science ®Google Scholar
• Gonzalez Cardona J, Smith MD, Wang J, et al. Quetiapine has an additive effect to triiodothyronine in inducing differentiation of oligodendrocyte precursor cells through induction of cholesterol biosynthesis. PLOS ONE. 2019;14(9):e0221747.
   PubMed Web of Science ®Google Scholar
• Safety and tolerability of quetiapine in multiple sclerosis. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT02087631
   Google Scholar
• Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006;26(4):1269.
   PubMed Web of Science ®Google Scholar
• Nagai A, Nakagawa E, Choi HB, et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60(4):386–392.
   PubMed Web of Science ®Google Scholar
• Sugawa M, Sakurai Y, Ishikawa-Ieda Y, et al. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res. 2002;44(4):391–403.
   PubMed Web of Science ®Google Scholar
• Mirzaie J, Raoofi A, Jamalpoor Z, et al. Protective impacts of erythropoietin on myelinization of oligodendrocytes and schwann cells in CNS and PNS following cuprizone-induced multiple sclerosis- histology, molecular, and functional studies. J Chem Neuroanat. 2020;104:101750.
   PubMed Web of Science ®Google Scholar
• Mustapha O, Oke B, Offen N, et al. Neurobehavioral and cytotoxic effects of vanadium during oligodendrocyte maturation: a protective role for erythropoietin. Environ Toxicol Pharmacol. 2014;38(1):98–111.
   PubMed Web of Science ®Google Scholar
• Genc K, Genc S, Baskin H, et al. Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res. 2006;55(1):33–38.
   PubMed Web of Science ®Google Scholar
• Moransard M, Bednar M, Frei K, et al. Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms. J Neuroinflammation. 2017;14(1):202.
   PubMedGoogle Scholar
• Li W, Maeda Y, Yuan RR, et al. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol. 2004;56(6):767–777.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Cui Y, et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 2005;1034(1):34–39.
   PubMed Web of Science ®Google Scholar
• Cho YK, Kim G, Park S, et al. Erythropoietin promotes oligodendrogenesis and myelin repair following lysolecithin-induced injury in spinal cord slice culture. Biochem Biophys Res Commun. 2012;417(2):753–759.
   PubMed Web of Science ®Google Scholar
• Sühs K-W, Hein K, Sättler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012;72(2):199–210.
   PubMed Web of Science ®Google Scholar
• Diem R, Molnar F, Beisse F, et al. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial—study protocol. BMJ Open. 2016;6(3):e010956.
   PubMed Web of Science ®Google Scholar
• Treatment of optic neuritis with erythropoietin: a randomised, double-blind, placebo-controlled trial. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT01962571
   Google Scholar
• Schreiber K, Magyari M, Sellebjerg F, et al. High-dose erythropoietin in patients with progressive multiple sclerosis: a randomized, placebo-controlled, phase 2 trial. Mult Scler J. 2016;23(5):675–685.
   PubMed Web of Science ®Google Scholar
• Abi Ghanem C, Degerny C, Hussain R, et al. Long-lasting masculinizing effects of postnatal androgens on myelin governed by the brain androgen receptor. PLoS Genet. 2017;13(11):e1007049.
   PubMed Web of Science ®Google Scholar
• Cerghet M, Skoff RP, Bessert D, et al. Proliferation and death of oligodendrocytes and myelin proteins are differentially regulated in male and female rodents. J Neurosci. 2006;26(5):1439.
   PubMed Web of Science ®Google Scholar
• Hussain R, Ghoumari AM, Bielecki B, et al. The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination. Brain. 2013;136(1):132–146.
   PubMedGoogle Scholar
• DonCarlos LL, Sarkey S, Lorenz B, et al. Novel cellular phenotypes and subcellular sites for androgen action in the forebrain. Neuroscience. 2006;138(3):801–807.
   PubMed Web of Science ®Google Scholar
• Bielecki B, Mattern C, Ghoumari AM, et al. Unexpected central role of the androgen receptor in the spontaneous regeneration of myelin. Proc Nat Acad Sci. 2016;113(51):14829.
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007;64(5):683–688.
   PubMed Web of Science ®Google Scholar
• Metzger-Peter K, Kremer LD, Edan G, et al. The TOTEM RRMS (Testosterone treatment on neuroprotection and myelin repair in relapsing remitting multiple sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2020;21(1):591.
   PubMedGoogle Scholar
• Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. 2012;8(5):255–263.
   PubMed Web of Science ®Google Scholar
• Tiwari-Woodruff S, Morales LBJ, Lee R, et al. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)α and ERβ ligand treatment. Proc Nat Acad Sci. 2007;104(37):14813.
   PubMed Web of Science ®Google Scholar
• Rankin KA, Mei F, Kim K, et al. Selective estrogen receptor modulators enhance CNS remyelination independent of estrogen receptors. J Neurosci. 2019;39(12):2184.
   PubMed Web of Science ®Google Scholar
• Hubler Z, Allimuthu D, Bederman I, et al. Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature. 2018;560(7718):372–376.
   PubMed Web of Science ®Google Scholar
• Voskuhl RR, Itoh N, Tassoni A, et al. Gene expression in oligodendrocytes during remyelination reveals cholesterol homeostasis as a therapeutic target in multiple sclerosis. Proc Nat Acad Sci. 2019;116(20):10130.
   PubMed Web of Science ®Google Scholar
• Bazedoxifene acetate as a remyelinating agent in multiple sclerosis. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT04002934
   Google Scholar
• Vaginal estriol in multiple sclerosis. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT03774407
   Google Scholar
• Lee JY, Petratos S. Thyroid hormone signaling in oligodendrocytes: from extracellular transport to intracellular signal. Mol Neurobiol. 2016;53(9):6568–6583.
   PubMed Web of Science ®Google Scholar
• Fernandez M, Giuliani A, Pirondi S, et al. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci U S A. 2004;101(46):16363.
   PubMed Web of Science ®Google Scholar
• D’Intino G, Lorenzini L, Fernandez M, et al. Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism. J Neuroendocrinol. 2011;23(9):778–790.
   PubMed Web of Science ®Google Scholar
• Harsan L-A, Steibel J, Zaremba A, et al. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci. 2008;28(52):14189.
   PubMed Web of Science ®Google Scholar
• Castelo-Branco G, Stridh P, Guerreiro-Cacais AO, et al. Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats. Neurobiol Dis. 2014;71:220–233.
   PubMed Web of Science ®Google Scholar
• Wooliscroft L, Altowaijri G, Hildebrand A, et al. Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: a dose-ranging study with assessment of reliability of visual outcomes. Mult Scler Relat Disord. 2020;41:102015.
   PubMed Web of Science ®Google Scholar
• Jepson S, Vought B, Gross CH, et al. LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. J Biol Chem. 2012;287(26):22184–22195.
   PubMed Web of Science ®Google Scholar
• Zhao X-H, Jin W-L, Ju G. An in vitro study on the involvement of LINGO-1 and Rho GTPases in Nogo-A regulated differentiation of oligodendrocyte precursor cells. Mol Cell Neurosci. 2007;36(2):260–269.
   PubMed Web of Science ®Google Scholar
• Lee X, Yang Z, Shao Z, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci. 2007;27(1):220.
   PubMed Web of Science ®Google Scholar
• Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13(10):1228–1233.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflammat. 2014;1(2):e18.
   PubMedGoogle Scholar
• Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189–199.
   PubMed Web of Science ®Google Scholar
• Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(9):845–856.
   PubMed Web of Science ®Google Scholar
• BIIB033 in acute optic neuritis (AON). [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT01721161
   Google Scholar
• Long-term assessment of remyelinating therapy. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT02657915
   Google Scholar
• Okuno T, Nakatsuji Y, Kumanogoh A. The role of immune semaphorins in multiple sclerosis. FEBS Lett. 2011;585(23):3829–3835.
   PubMed Web of Science ®Google Scholar
• Yamaguchi W, Tamai R, Kageura M, et al. Sema4D as an inhibitory regulator in oligodendrocyte development. Mol Cell Neurosci. 2012;49(3):290–299.
   PubMed Web of Science ®Google Scholar
• Giraudon P, Vincent P, Vuaillat C, et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol. 2004;172(2):1246.
   PubMed Web of Science ®Google Scholar
• Smith ES, Jonason A, Reilly C, et al. SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis. 2015;73:254–268.
   PubMed Web of Science ®Google Scholar
• LaGanke C, Samkoff L, Edwards K, et al. Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial. Neurol Neuroimmunol Neuroinflammat. 2017;4(4):e367.
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Deitinghoff L, Davis D, et al. Neogenin mediates the action of repulsive guidance molecule. Nat Cell Biol. 2004;6(8):756–762.
   PubMed Web of Science ®Google Scholar
• Siebold C, Yamashita T, Monnier PP, et al. RGMs: structural insights, molecular regulation, and downstream signaling. Trends Cell Biol. 2017;27(5):365–378.
   PubMed Web of Science ®Google Scholar
• Muramatsu R, Kubo T, Mori M, et al. RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis. Nat Med. 2011;17(4):488–494.
   PubMed Web of Science ®Google Scholar
• Tanabe S, Yamashita T. Repulsive guidance molecule-a is involved in Th17-cell-induced neurodegeneration in autoimmune encephalomyelitis. Cell Rep. 2014;9(4):1459–1470.
   PubMed Web of Science ®Google Scholar
• Demicheva E, Cui Y-F, Bardwell P, et al. Targeting repulsive guidance molecule a to promote regeneration and neuroprotection in multiple sclerosis. Cell Rep. 2015;10(11):1887–1898.
   PubMed Web of Science ®Google Scholar
• Tanabe S, Fujita Y, Ikuma K, et al. Inhibiting repulsive guidance molecule-a suppresses secondary progression in mouse models of multiple sclerosis. Cell Death Dis. 2018;9(11):1061.
   PubMedGoogle Scholar
• Ziemann A, Rosebraugh M, Barger B, et al. A Phase 1, multiple-dose study of Elezanumab (ABT-555) in patients with relapsing forms of multiple sclerosis (S56.001). Neurology. 2019;92(15 Supplement):S56.001.
   Google Scholar
• A study to assess the safety and efficacy of Elezanumab when added to standard of care in progressive forms of multiple sclerosis. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT03737812
   Google Scholar
• Mitsunaga Y, Ciric B, Van Keulen V, et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J. 2002;16(10):1325–1327.
   PubMed Web of Science ®Google Scholar
• Pirko I, Ciric B, Gamez J, et al. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J. 2004;18(13):1577–1579.
   PubMed Web of Science ®Google Scholar
• Bieber AJ, Warrington A, Asakura K, et al. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia. 2002;37(3):241–249.
   PubMed Web of Science ®Google Scholar
• Mullin AP, Cui C, Wang Y, et al. rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis. 2017;105:142–155.
   PubMed Web of Science ®Google Scholar
• Cui C, Wang J, Mullin AP, et al. The antibody rHIgM22 facilitates hippocampal remyelination and ameliorates memory deficits in the cuprizone mouse model of demyelination. Brain Res. 2018;1694:73–86.
   PubMed Web of Science ®Google Scholar
• Warrington AE, Asakura K, Bieber AJ, et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Nat Acad Sci. 2000;97(12):6820.
   PubMed Web of Science ®Google Scholar
• Warrington AE, Bieber AJ, Ciric B, et al. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res. 2007;85(5):967–976.
   PubMed Web of Science ®Google Scholar
• Vala M, Jordan LR, Warrington AE, et al. Surface plasmon resonance sensing on naturally derived membranes: a remyelination-promoting human antibody binds myelin with extraordinary affinity. Anal Chem. 2018;90(21):12567–12573.
   PubMed Web of Science ®Google Scholar
• Watzlawik JO, Warrington AE, Rodriguez M. PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation. PLOS ONE. 2013;8(2):e55149.
   PubMed Web of Science ®Google Scholar
• Howe CL, Bieber AJ, Warrington AE, et al. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis. 2004;15(1):120–131.
   PubMed Web of Science ®Google Scholar
• Eisen A, Greenberg BM, Bowen JD, et al. A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis. Multiple Sclerosis Journal – Experimental Transl Clin. 2017;3(4):2055217317743097.
   Google Scholar
• An intravenous infusion study of rHIgM22 in patients with multiple sclerosis immediately following a relapse. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT02398461
   Google Scholar
• Derfuss T, Mehling M, Papadopoulou A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020;19(4):336–347.
   PubMed Web of Science ®Google Scholar
• Windrem MS, Schanz SJ, Zou L, et al. Human glial progenitor cells effectively remyelinate the demyelinated adult brain. Cell Rep. 2020;31(7):107658.
   PubMed Web of Science ®Google Scholar
• A study to assess the safety and efficacy of Elezanumab when added to standard of care in relapsing forms of multiple sclerosis. [cited 2021 Apr 28]. Available from: https://ClinicalTrials.gov/show/NCT03737851
   Google Scholar
• Wootla B, Denic A, Watzlawik JO, et al. Antibody-mediated oligodendrocyte remyelination promotes axon health in progressive demyelinating disease. Mol Neurobiol. 2016;53(8):5217–5228.
   PubMed Web of Science ®Google Scholar
• Butt AM, De La Rocha IC, Rivera A. Oligodendroglial cells in Alzheimer’s disease. Adv Exp Med Biol. 2019;1175:325–333.
   PubMed Web of Science ®Google Scholar
• Conway BL, Zeydan B, Uygunoğlu U, et al. Age is a critical determinant in recovery from multiple sclerosis relapses. Mult Scler. 2019;25(13):1754–1763.
   PubMed Web of Science ®Google Scholar
• Hill RA, Li AM, Grutzendler J. Lifelong cortical myelin plasticity and age-related degeneration in the live mammalian brain. Nat Neurosci. 2018;21(5):683–695.
   PubMed Web of Science ®Google Scholar
• Long P, Corfas G. Neuroscience. To learn is to myelinate. Science. 2014;346(6207):298–299.
   PubMed Web of Science ®Google Scholar
• McKenzie IA, Ohayon D, Li H, et al. Motor skill learning requires active central myelination. Science. 2014;346(6207):318–322.
   PubMed Web of Science ®Google Scholar
• Xiao L, Ohayon D, McKenzie IA, et al. Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning. Nat Neurosci. 2016;19(9):1210–1217.
   PubMed Web of Science ®Google Scholar